Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

• Published in: The Lancet (British edition) 2006-11, Vol.368 (9549), p.1771-1781
• Main Authors: Cannon, Christopher P, Curtis, Sean P, FitzGerald, Garret A, Krum, Henry, Kaur, Amarjot, Bolognese, James A, Reicin, Alise S, Bombardier, Claire, Weinblatt, Michael E, van der Heijde, Désirée, Erdmann, Erland, Laine, Loren
• Format: Article
• Language: English
• Subjects: Aged; Anti-inflammatory agents; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Arthritis, Rheumatoid - drug therapy; Autoimmune diseases; Cardiovascular disease; Cardiovascular Diseases - chemically induced; Clinical trials; Cyclooxygenase 2 Inhibitors - adverse effects; Cyclooxygenase 2 Inhibitors - therapeutic use; Design; Diclofenac - adverse effects; Diclofenac - therapeutic use; Drug therapy; Female; Health risks; Humans; Informed consent; Long term; Male; Middle Aged; Multicenter Studies as Topic; Nonsteroidal anti-inflammatory drugs; Osteoarthritis; Osteoarthritis - drug therapy; Pharmaceutical industry; Pyridines - adverse effects; Pyridines - therapeutic use; Randomized Controlled Trials as Topic; Regulatory agencies; Rheumatoid arthritis; Studies; Sulfones - adverse effects; Sulfones - therapeutic use
• ISSN: 0140-6736; 1474-547X
• DOI: 10.1016/S0140-6736(06)69666-9

Cyclo-oxygenase-2 (COX-2) selective inhibitors have been associated with an increased risk of thrombotic cardiovascular events in placebo-controlled trials, but no clinical trial has been reported with the primary aim of assessing relative cardiovascular risk of these drugs compared with traditional non-steroidal anti-inflammatory drugs (NSAIDs). The MEDAL programme was designed to provide a precise estimate of thrombotic cardiovascular events with the COX-2 selective inhibitor etoricoxib versus the traditional NSAID diclofenac. We designed a prespecified pooled analysis of data from three trials in which patients with osteoarthritis or rheumatoid arthritis were randomly assigned to etoricoxib (60 mg or 90 mg daily) or diclofenac (150 mg daily). The primary hypothesis stated that etoricoxib is not inferior to diclofenac, defined as an upper boundary of less than 1·30 for the 95% CI of the hazard ratio for thrombotic cardiovascular events in the per-protocol analysis. Intention-to-treat analyses were also done to assess consistency of results. These trials are registered at http://www.clinicaltrials.gov with the numbers NCT00092703, NCT00092742, and NCT00250445. 34 701 patients (24 913 with osteoarthritis and 9 787 with rheumatoid arthritis) were enrolled. Average treatment duration was 18 months (SD 11·8). 320 patients in the etoricoxib group and 323 in the diclofenac group had thrombotic cardiovascular events, yielding event rates of 1·24 and 1·30 per 100 patient-years and a hazard ratio of 0·95 (95% CI 0·81–1·11) for etoricoxib compared with diclofenac. Rates of upper gastrointestinal clinical events (perforation, bleeding, obstruction, ulcer) were lower with etoricoxib than with diclofenac (0·67 vs 0·97 per 100 patient-years; hazard ratio 0·69 [0·57–0·83]), but the rates of complicated upper gastrointestinal events were similar for etoricoxib (0·30) and diclofenac (0·32). Rates of thrombotic cardiovascular events in patients with arthritis on etoricoxib are similar to those in patients on diclofenac with long-term use of these drugs.